LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
General Hepatology
5
LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
General Hepatology
7
Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023
View
General Hepatology
5
LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
General Hepatology
5
LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
